aldh4a1 Antibody

What is ALDH4A1 and why is it important in research?

ALDH4A1, also known as P5CDH (Delta-1-pyrroline-5-carboxylate dehydrogenase), is a mitochondrial dehydrogenase that catalyzes the second step of the proline degradation pathway, converting pyrroline-5-carboxylate to glutamate. This enzymatic function is vital for maintaining cellular homeostasis and regulating proline levels . Deficiency of this enzyme is associated with type II hyperprolinemia, a genetic disorder characterized by elevated proline and its precursors, which can result in neurological complications such as mental retardation and seizures . Recent research has also identified ALDH4A1 as an atherosclerosis auto-antigen, making it significant for cardiovascular disease research .

Which tissues and cell lines show high ALDH4A1 expression?

ALDH4A1 antibodies have demonstrated positive Western blot detection in multiple tissues and cell lines:

• Human tissues: heart, brain, liver, skeletal muscle

• Cell lines: HepG2, K-562

• Mouse tissues: skeletal muscle, small intestine

• Rat tissues: heart

This expression pattern makes these antibodies valuable for comparative tissue studies across species.

What are the commonly used applications for ALDH4A1 antibodies?

ALDH4A1 antibodies are versatile reagents with multiple validated applications:

How should researchers optimize ALDH4A1 antibody protocols for challenging samples?

For challenging samples or weak signals, consider these optimization strategies:

• Antigen retrieval: For IHC applications, both TE buffer (pH 9.0) and citrate buffer (pH 6.0) have proven effective, with TE buffer showing superior results in human liver tissues .

• Signal amplification: For low-expressing samples, increase antibody concentration gradually while monitoring background.

• Extended incubation: For Western blot, overnight primary antibody incubation at 4°C can improve detection of low-abundance ALDH4A1.

• Sample preparation: Mitochondrial enrichment protocols can significantly enhance detection sensitivity, as ALDH4A1 is primarily localized to the mitochondrial matrix .

What controls should be included when validating ALDH4A1 antibody specificity?

Comprehensive validation requires multiple controls:

• Positive tissue controls: Human liver, heart, and skeletal muscle tissues show reliable ALDH4A1 expression .

• Negative controls: Omit primary antibody while maintaining secondary antibody.

• Knockdown/knockout validation: Some ALDH4A1 antibodies have been validated using KD/KO approaches, providing the highest specificity confirmation .

• Recombinant protein: Competition assays using recombinant ALDH4A1-FLAG protein have been used to confirm antibody specificity, with measured binding inhibition demonstrating specificity .

• Cross-reactivity assessment: Testing against related ALDH family members is recommended to ensure specificity.

How are ALDH4A1 antibodies used in atherosclerosis research?

ALDH4A1 has emerged as an important auto-antigen in atherosclerosis research:

• Autoantibody detection: ELISA assays using ALDH4A1-coated plates can detect anti-ALDH4A1 autoantibodies in plasma from atherosclerosis models and patients .

• Tissue distribution analysis: IHC with anti-ALDH4A1 antibodies has revealed altered distribution patterns during atherosclerosis progression, with significant changes observed in the medial and intimal layers of atherosclerotic vessels .

• Therapeutic potential: Infusion of anti-ALDH4A1 antibodies (specifically the A12 antibody) into Ldlr-/- mice delayed plaque formation and reduced circulating free cholesterol and LDL, suggesting potential therapeutic applications .

• Biomarker studies: Circulating ALDH4A1 levels are increased in both mice and humans with atherosclerosis, supporting its potential use as a disease biomarker .

What methodological approaches can quantify ALDH4A1 expression changes in disease states?

Researchers studying disease-related ALDH4A1 alterations should consider:

• Quantitative Western blot: Normalizing ALDH4A1 signals to housekeeping proteins allows for relative quantification across disease and normal states.

• Competition immunoassays: These have been established for measuring ALDH4A1-specific antibodies, with protocols using various competitors including BSA, MDA-LDL, and ALDH4A1-FLAG .

• Immunohistochemistry quantification: Studies have quantified ALDH4A1 abundance in different vessel layers (medial vs. intimal) through digital image analysis, revealing layer-specific changes during disease progression .

• Flow cytometry: For immune response studies, flow cytometry has been used to analyze germinal center B cells (Fas+GL7+) and IgG1+ B cells following ALDH4A1 immunization .

How can researchers distinguish between different isoforms or post-translational modifications of ALDH4A1?

Detecting specific ALDH4A1 variants requires specialized approaches:

• Antibody selection: Use antibodies raised against specific regions that differ between isoforms.

• Molecular weight confirmation: The calculated molecular weight of human ALDH4A1 is 62 kDa (563 amino acids), which should be confirmed on Western blots .

• 2D gel electrophoresis: This technique can separate proteins by both molecular weight and isoelectric point, helping differentiate post-translationally modified forms.

• Phospho-specific antibodies: While not prominently featured in the search results, consideration of post-translational modifications may be important for comprehensive analysis.

• Mass spectrometry validation: For definitive identification of specific isoforms and modifications, immunoprecipitated ALDH4A1 can be analyzed by mass spectrometry, as demonstrated in atherosclerosis research .

What are the common pitfalls when working with ALDH4A1 antibodies and how can they be addressed?

Several technical challenges may arise when working with ALDH4A1 antibodies:

• Mitochondrial localization issues: As a mitochondrial protein, proper sample preparation is crucial for accessing ALDH4A1. Adequate permeabilization protocols are essential for immunofluorescence and flow cytometry applications .

• Cross-reactivity with other ALDH family members: The aldehyde dehydrogenase family contains multiple members with structural similarities. Validation through specific controls is essential .

• Species-specific variations: While human, mouse, and rat ALDH4A1 show high homology (mouse: 92%, rat: 91%), antibody performance may vary between species. Species-specific validation is recommended before extensive studies .

• Sample-dependent variability: Documentation indicates that results can be sample-dependent. Researchers should test antibody performance in their specific experimental system before conducting full studies .

How are ALDH4A1 antibodies being used in cardiovascular biomarker development?

Recent research has revealed the potential of ALDH4A1 as a cardiovascular biomarker:

• Plasma ALDH4A1 quantification: Studies have shown increased circulating ALDH4A1 in both mice and humans with atherosclerosis .

• Anti-ALDH4A1 autoantibody detection: ELISA measurement of anti-ALDH4A1 IgM and IgG antibodies has demonstrated significant differences between atherosclerotic and normal subjects .

• Longitudinal monitoring: Anti-ALDH4A1 IgM antibody levels have been tracked over time during disease progression, showing potential for tracking atherosclerosis development .

• Clinical correlation: Logistic regression analysis adjusted with cardiovascular risk factors has been performed with atherosclerosis presence as a dependent variable, demonstrating ALDH4A1's potential as a clinical biomarker .

What is the significance of ALDH4A1 in metabolism research beyond proline pathways?

While primarily known for its role in proline metabolism, ALDH4A1 has broader significance:

What are the best practices for using ALDH4A1 antibodies in multiplex immunofluorescence studies?

For researchers conducting multiplex studies:

• Antibody selection: Choose antibodies raised in different host species to avoid cross-reactivity of secondary antibodies.

• Sequential staining: For co-localization with other mitochondrial markers, sequential rather than simultaneous staining may yield cleaner results.

• Controls: Include single-stain controls to assess and correct for spectral overlap.

• Antibody validation: Confirm that antibody performance in multiplex settings matches that of single-antibody applications.

• Signal amplification: For weak signals, consider using tyramide signal amplification (TSA) systems that are compatible with multiplexing.

How should researchers standardize ALDH4A1 antibody-based quantitative assays across laboratories?

For consistent quantitative measurements:

• Reference standards: Include recombinant ALDH4A1 protein standards of known concentration.

• Consistent controls: Establish common positive control samples (e.g., specific cell lines or tissue lysates) for inter-laboratory calibration.

• Antibody lot testing: New antibody lots should be validated against previous lots using standardized samples.

• Protocol sharing: Detailed methodological protocols should be shared, including specific buffer compositions and incubation times.

• Collaborative validation: Consider multi-center studies to establish reproducibility, as demonstrated in atherosclerosis biomarker research .